look after him until he died in 1995. Within two months of his death, Dona developed ataxia and a right-sided paralysis from what proved to be a central nervous system lymphomaÐa condition that at that time was expected to cause death within 90 days. Three weeks after this diagnosis the ®rst protease inhibitors were released, and she has been on triple therapy for over 4 years. She now has neuropathy, lipodystrophy, abnormal cervical smears and hearing loss, and has been in hospice care for 4 years. However, her brain lymphoma has regressed and recently, for the ®rst time, she had a`negative viral load'.
UNEVEN TRAJECTORY OF ILLNESS
As the above case demonstrates, HIV disease may not follow a predicted timetable. Providers may not be able to predict outcome of the highly active antiretroviral therapies (HAART). The impact of HAART is equally uncertain for the incidence of new cases of AIDS-de®ning illness as it is on existing conditions. The most common AIDS-related malignancies are Kaposi's sarcoma, non-Hodgkin lymphoma (NHL) and cervical carcinoma. The only malignancies that have decreased in incidence since the introduction of HAART have been Kaposi's sarcoma and primary brain lymphoma; there seems to be no change in the incidence of NHL, Hodgkin's lymphoma or invasive cervical carcinoma 1 . NHL is typically diagnosed at a time when the immune system is not severely depressed 2 . The incidence of certain non-AIDS-de®ning cancers, such as anal cancer, multiple myeloma, and cancers of the stomach, lung and larynx may even be increasing with the increasing longevity conferred by HAART 3 . Wasting syndrome has emerged as the most frequent initial clinical diagnosis among people already on HAART 4 .
From this we may conclude that, even though current antiretroviral therapy is much more successful at prolonging reasonably good health, severe illnesses are likely to emerge eventually in this patient population. These may well differ in frequency from the AIDS-de®ning illnesses seen in the early years of the epidemic.
DISCOMFORTS OF ANTIRETROVIRAL THERAPY
Drugs for HIV can have side-effects that spoil enjoyment of life and hamper adherence to complex treatment regimens. Three types of disturbance are of special note.
Peripheral neuropathy is the most frequent neurological complication associated with HIV infection. It can cause burning, numbness, tingling, or pain. Sometimes the neuropathy is due to the HIV infection itself, sometimes to the antiretroviral agents (most commonly didanosine, zalcitabine or stavudine). Pain may vary from mild discomfort to inability to ambulate. If it is medicationinduced, drug holidays or medication changes may be indicated; but for patients who have experienced multiple drug failures, medication change may not be feasible. Neuropathies seldom respond well to treatment 5 .
Alterations in body fat distribution can lead to changes in physical appearance which can be very disturbing to patients. Several syndromes have been identi®ed, and in some studies these have been linked to protease inhibitor useÐthough in others over half the patients with lipodystrophy had no history of antiretroviral use 6 . Lipodystrophy may show itself with loss of subcutaneous fat in the face or extremities, an increase in abdominal girth (known as the protease paunch), dorsocervical fat pad enlargement on the back of the neck (buffalo hump), or increase in breast size in women. Strategies ranging from hormone therapies to switching of antiretrovirals have met with mixed success.
Other conditions that have been attributed to long-term antiretroviral therapy include diabetes, advanced cardiovascular disease, lipid abnormalities and hair loss. The exact incidence of these conditions in the treated population is still debated. We can expect to see more long-term complications of antiretroviral therapy in the future as patients live longer.
PALLIATIVE OR CURATIVE?
HIV presents an especially dif®cult challenge when the patient becomes severely ill. The virus hampers the ability to resist not only opportunist infections but also those due to common pathogens, and many of the symptoms that arise will be potentially treatable. For example, when an individual with severe wasting syndrome suddenly loses vision, the cause may be an opportunistic viral infection such as cytomegalovirus. However ill the patient, prevention of blindness may become a major concern, requiring aggressive diagnostic procedures. These in turn generate ambiguities in clinical decision-making. Box 1 lists some symptoms that are especially troubling to patients.
ETHNIC/RACIAL DIFFERENCES
Deaths among people with AIDS in the USA began to fall in 1996, for the ®rst time in the history of the epidemic. The incidence of AIDS also decreased in the same year. In States that have HIV reporting, HIV diagnosis rates have been stable for several years but a higher proportion of cases are now being seen among women and people from minority groups. Women in New York had a shorter survival time than men, and the explanation was thought to lie in several factors, including poverty, dif®culty with the healthcare system, and the role of women as caregivers (often for HIV-infected spouses or children) 7 . Other analyses of the New York data indicate that survival time has increased more for younger people than for older people, and for heterosexuals and men who have sex with men than for intravenous drug users 8 . After hospital admission, Hispanics seem to have a worse survival rate than white or African Americans 9 . The combined impact of drug use and sexually transmitted diseases, especially in patients aged 18±24, is a trend of great concern. Access to care is a great and growing issue in these groups 10 .
MENTAL ILLNESS
Several studies have documented the increased frequency of mental illness in patients with HIV disease 11, 12 Ðnotably, depression, substance abuse, anxiety and dementia. Dementia is still a common initial symptom in the diagnosis of AIDS 11 . Depression is of particular importance since as well as predisposing to suicide it can in¯uence immune function. Fortunately, HIV-infected patients seem to respond to antidepressant regimens at about the same frequency as the non-HIV-infected.
J O U R N A L O F T H E R O Y A L S O C I E T Y O F M E D I C I N E
V o l u m e 9 4 S e p t e m b e r 2 0 0 1 Box 1 Common symptoms of concern to patients Confusion/dementia 
CAREGIVER STRESS
Certain features of the HIV epidemic impose exceptional stresses on caregivers. In one US study of informal caregiving, over 6% of the population in central cities had provided care to HIV-infected persons, as opposed to 3.2% for the entire country. Two-thirds of these people had performed domestic tasks but just over a quarter had provided personal care. With HIV the caregivers differed from others in being more likely to be young, male and providing care that was emotionally stressful 13 . When the caregiver of an HIV patient is a family member, special dif®culties arise. Issues of sexual or drug behaviour may emerge simultaneously with the information on the HIV diagnosis, and be met by fears of social stigma, contagion, infection, abandonment, guilt, and overwhelming fatigue 14 . In many instances, several members of the family are HIV-infected, and the stress of anticipatory grief may be exacerbated if the caregiver has already lost numerous friends to HIV. The caregiver, if a partner, may also be angry at having been exposed unwittingly to the infection. Finally, when the caregiver is a gay man, he may face the prospect of losing his home, possessions or money as well as that of having no say in decisions about care in the terminal stage of his partner's illness.
Women who are HIV-infected tend to neglect their own care if they also have HIV-infected children in the home 15 . In one rural county in the southern USA most HIV-infected children were still being looked after by their HIV-positive mothers 16 . For an infected caregiver, daily involvement with the patient brings home his or her own likely fate.
CONCLUSION
Despite the increased survival rates achieved in the past ®ve years, perplexing issues remain for delivery of care in HIV infection. By becoming more of a chronic disease it creates new medical challenges, in which palliation and attempts at cure cannot be separated. Disparities of geography, risk group, gender and ethnicity deprive some patients of the full bene®ts of medical advances. Even when access is readily available, the patient is not cured and there is the ever-present threat of infection or tumour. These concerns will persist until we have a cure, available and affordable to all, and methods to ensure that unsuspecting individuals will not become infected.
